← Therapy pipeline
Investigational · Obesity development

UBT251

Novo Nordisk / United Laboratories

Once-weekly triple agonist in Phase 3 obesity development in China.

GLP-1GIPglucagon
Other study areas
Type 2 diabetes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorNovo Nordisk / United Laboratories
TargetsGLP-1 + GIP + glucagon
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

China Phase 2 obesity studyLeast-squares mean change in body weight at week 24Body weight decreased 19.7% · 24 weeks · Phase 2
Phase 2 · Injection · Peer-reviewed publication

Least-squares mean change in body weight at week 24 · 24 weeks

Study focus: Weight management

Highest reported UBT251 group; range across groups: −13.6% to −19.7%
19.7%
Placebo
2%

Adults with overweight or obesity in China · Once-weekly injection; the published range spans UBT251 dose groups and this summary does not assign the maximum to a specific dose · Trial N=205 · Peer-reviewed, randomized, double-blind, placebo-controlled Phase 2 report; week-24 least-squares mean percentage change. Results & methods ↗

A 24-week Phase 2 trial in adults with overweight or obesity in China. The published range spans dose groups; the maximum is not assigned to a specific dose in this summary. Long-term and global obesity-study results remain pending.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagonTargeted
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 3China Phase 3 active, not recruiting. Separate global early-phase study ongoing.
Milestone → next

Latest: Peer-reviewed China Phase 2 obesity results published: 24-week body-weight change ranged from 13.6% to 19.7% across UBT251 groups versus 2.0% with placebo. The China Phase 3 obesity trial started September 4, 2026.

Next: China Phase 3 and global obesity study results.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies1 record

Phase 3

China Phase 3 obesity study

Weight management
Study: Active, not recruitingResults: No registry results posted yetStatus reviewed November 2026

Placebo-controlled study in China with estimated enrollment of 600 adults. The primary outcome is percentage change in body weight at week 52.

Phase 2 studies2 records

Phase 2

China obesity study

Weight management
Study: CompletedResults: Peer-reviewed Phase 2 results: 24-week body-weight change ranged from 13.6% to 19.7% across UBT251 groups versus 2.0% with placeboStatus reviewed October 2026

Overweight/obesity in China; randomized, double-blind, placebo-controlled; peer-reviewed results published in Cell Metabolism.

Phase 2

Global obesity study

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Global Phase 2 obesity protocol; registry recruiting. Separate from the published China Phase 2 trial.